Novo Nordisk stock falls as growth targets disappoint

Published on 09/23/2026 at 14:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novo Nordisk stock closed at DKK 258.80 on September 22, 2026, down 0.46 percent. Second-quarter revenue rose to DKK 78.49 billion.

Flatlay mit Spritze, Teststreifen, Notizbuch und Apfel auf weißem Untergrund — Novo Nordisk A/S (DK0062498333): Flatlay mit Spritze, Blutzucker-Teststreifen, Notizbuch und Apfel auf Weiß, Illustration mit AI erstellt.

Novo Nordisk stock (ISIN DK0062498333) closed at DKK 258.80 on Nasdaq Copenhagen on September 22, 2026, down 0.46 percent from the previous close. The market is still digesting the company's September 21 capital markets targets, which were followed by an 8 percent share-price decline, according to Reuters on September 23, 2026.

Growth targets reset expectations

Novo Nordisk said on September 21 that it aims to launch more than 5 blockbuster medicines by 2030 and generate more than DKK 150 billion in pipeline sales by 2035. The target implies a major expansion effort, but the longer-dated opportunity must offset pressure on the established Wegovy franchise.

Reuters reported on September 23, 2026, that the planned DKK 150 billion of additional revenue by 2035 would only partly offset sales pressure as the core Wegovy franchise approaches patent expiry. That comparison explains why the market treated the pipeline target as a longer-term requirement rather than an immediate earnings upgrade.

Quarterly profit remains under pressure

For the quarter ending June 30, 2026, Novo Nordisk reported revenue of DKK 78.49 billion and net profit of DKK 20.99 billion. Revenue was higher than the DKK 76.86 billion recorded in the comparable period, while net profit fell from DKK 26.50 billion, according to The Globe and Mail on September 23, 2026.

The earnings comparison is the central operating counterweight to the pipeline story: second-quarter revenue increased by DKK 1.63 billion year over year, but net profit decreased by DKK 5.51 billion. For investors, the issue is therefore not only future product launches but also how quickly sales growth can translate into profit while competition and pricing pressure rise.

Analysts cut targets after the selloff

Deutsche Bank cut its price target from DKK 265 to DKK 245 and retained a Sell rating after the capital markets day, according to the September 23, 2026 report carried by Ad Hoc News. CFRA separately cut its recommendation from Hold to Sell and set a USD 38 target on September 23, 2026, as reported by MarketScreener.

Stock stays near the yearly low

The September 22 close of DKK 258.80 remained above the reported 52-week low of DKK 224.30 and below the 52-week high of DKK 410.00. The next quarterly results are scheduled for November 3, 2026, according to calendar data cited by Ad Hoc News.